2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- 66.67%1-Year Change
- BiotechnologyIndustry
Eastgate Biotech (ETBI)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreInformation as of 10/12/2026
Company Profile
Eastgate Biotech Corp., produces and distributes nutraceuticals that are based on natural therapies and absorbed naturally by the body. The company is developing pharmaceutical products, such as Lorazepam spray for acute seizures; and EGP-1214, intraoral (sublingual) insulin tablet for diabetes and metabolic syndrome. It is also developing natural healing medication and other products, including E-drops NANO, a plant essential oil for urinary and vaginal tract infections; Essential, a Vitamin D3, to improve the body's digestive, cardiovascular, and immune systems; GluCora to lower daily intake of insulin; VCleanzz, an antibacterial wash for fruits and vegetables; Cleanezze, a natural hand sanitizer; and Warts X, a natural herbal product to treats warts. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was incorporated in 1999 and is based in Toronto, Canada.
Key Executives
- Rosella C. Perri
- William D. Abajian
- Joseph Schwarz
Current Ownership Distribution
- Other2.0B (97.94%)
- Insiders42.4M (2.06%)
- Institutions0 (0.00%)
- Mutual Funds0 (0.00%)